Exscientia Plc Quick Ratio (EXAI) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Exscientia Plc  (NASDAQ: EXAI)

Exscientia Plc's Quick Ratio

EXAI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2024, Quick Ratio fell to 2.3 below Exscientia Plc average.

Within Biotechnology & Pharmaceuticals industry 123 other companies have achieved higher Quick Ratio than Exscientia Plc in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 0 to 1652.

Explain Quick Ratio?
How much Cash & cash equivalents EXAI´s has?
What are EXAI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EXAI Quick Ratio (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2
Y / Y Current Liabilities Change 4.91 % -16.94 % -25.08 % -7.63 % -0.13 %
Y / Y Cash & cash equivalent Change -44.29 % -63.34 % -31.72 % -71.43 % -51.43 %
Quick Ratio MRQ 2.3 2.99 4.34 2.29 4.34
EXAI's Total Ranking # 1652 # 0 # # #
Seq. Current Liabilities Change 21.83 % -12.54 % 2.31 % -3.77 % -3.55 %
Seq. Cash & cash equivalent Change -6.26 % -39.69 % 94.27 % -49.27 % -38.31 %



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 124
Healthcare Sector # 595
Overall Market # 1652


Quick Ratio Statistics
High Average Low
12.51 6.3 0.35
0   (Dec 31 2021)




Financial Statements
Exscientia Plc's Current Liabilities $ 88 Millions Visit EXAI's Balance sheet
Exscientia Plc's Cash & cash equivalent $ 204 Millions Visit EXAI's Balance sheet
Source of EXAI's Sales Visit EXAI's Sales by Geography


Cumulative Exscientia Plc's Quick Ratio

EXAI's Quick Ratio for the trailling 12 Months

EXAI Quick Ratio

 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth -12.2 % -13.34 % -9.94 % 18.1 % 31.38 %
Y / Y Cash & cash equivalent TTM Growth -54.72 % -55.25 % -43.55 % -22.36 % -6.2 %
Quick Ratio TTM 2.97 3.52 4.48 4.6 5.77
Total Ranking TTM # 413 # # # # 569
Seq. Current Liabilities TTM Growth 1.29 % -4.41 % -7.64 % -1.81 % -0.03 %
Seq. Cash & cash equivalent TTM Growth -14.35 % -24.96 % -10.01 % -21.72 % -15.35 %

Quick ratio ranking by company, industry and sector >> Back to EXAI Financial Strength Comparisons >> Go to Compare EXAI Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2024 to $88.35 millions, cumulative Quick Ratio decreased to 2.97 below the Exscientia Plc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 168 other companies have achieved higher Quick Ratio than Exscientia Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 0 to 4202.

Explain Quick Ratio?
How much Cash & cash equivalents EXAI´s has?
What are EXAI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 169
Healthcare Sector # 1089
Within the Market # 1652


trailing twelve months Quick Ratio Statistics
High Average Low
4.41 4.2 3.99
(Dec 31 2022)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2024 MRQ Cash & cash equivalentSep 30 2024 MRQ Current Liabilities
Vor Biopharma Inc   6.17 $ 62.809  Millions$ 10.182  Millions
Genenta Science S p a   6.03 $ 14.179  Millions$ 2.351  Millions
Metagenomi Therapeutics Inc   6.01 $ 274.587  Millions$ 45.692  Millions
Molecular Partners Ag  5.92 $ 70.439  Millions$ 11.893  Millions
Monte Rosa Therapeutics Inc   5.82 $ 242.186  Millions$ 41.641  Millions
Beam Therapeutics Inc   5.57 $ 925.757  Millions$ 166.244  Millions
Adverum Biotechnologies Inc   5.54 $ 153.241  Millions$ 27.657  Millions
Fennec Pharmaceuticals Inc   5.42 $ 40.320  Millions$ 7.435  Millions
Black Diamond Therapeutics Inc   5.42 $ 112.682  Millions$ 20.800  Millions
Taysha Gene Therapies Inc   5.38 $ 157.688  Millions$ 29.335  Millions
Springworks Therapeutics Inc   5.33 $ 376.619  Millions$ 70.613  Millions
Compugen Ltd  5.24 $ 103.255  Millions$ 19.712  Millions
Surrozen Inc   5.07 $ 31.012  Millions$ 6.120  Millions
Passage Bio Inc   5.00 $ 84.826  Millions$ 16.951  Millions
Tenaya Therapeutics Inc   4.91 $ 79.469  Millions$ 16.177  Millions
Kalaris Therapeutics Inc   4.89 $ 6.908  Millions$ 1.412  Millions
Cardiff Oncology Inc   4.88 $ 57.667  Millions$ 11.818  Millions
X4 Pharmaceuticals Inc  4.81 $ 134.977  Millions$ 28.036  Millions
Dyadic International Inc   4.78 $ 9.922  Millions$ 2.077  Millions
Atyr Pharma Inc   4.67 $ 65.987  Millions$ 14.118  Millions
Inhibrx Biosciences Inc   4.65 $ 196.332  Millions$ 42.260  Millions
Prime Medicine Inc   4.50 $ 170.619  Millions$ 37.877  Millions
Pharmacyte Biotech Inc   4.36 $ 20.840  Millions$ 4.776  Millions
Cardiol Therapeutics inc   4.36 $ 23.424  Millions$ 5.370  Millions
Tradeup Acquisition Corp  4.29 $ 1.798  Millions$ 0.419  Millions
Sana Biotechnology Inc   4.23 $ 199.007  Millions$ 47.004  Millions
Arcellx Inc   4.19 $ 574.254  Millions$ 137.017  Millions
Scholar Rock Holding Corp  4.17 $ 139.065  Millions$ 33.331  Millions
Recursion Pharmaceuticals Inc   3.93 $ 427.647  Millions$ 108.888  Millions
Twist Bioscience Corporation  3.89 $ 276.399  Millions$ 71.006  Millions

Date modified: 2026-09-18T16:28:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.